Eagle Pharmaceuticals Inc (NAS:EGRX)
$ 3.92 0.18 (4.81%) Market Cap: 50.80 Mil Enterprise Value: 104.72 Mil PE Ratio: 4.31 PB Ratio: 0.20 GF Score: 60/100

Eagle Pharmaceuticals Inc Investor Day Transcript

Dec 06, 2022 / 01:00PM GMT
Release Date Price: $33.76 (-0.59%)
Scott L. Tarriff
Eagle Pharmaceuticals, Inc. - Founder, President, CEO & Director

Good morning, everyone. Thank you for joining us, both here at the Palace Hotel in beautiful New York, and those on the live webcast, that couldn't be with us here today.

Before we get started, I'd like to refer to our forward-looking statements. If you can all take a moment to read them, please. Thank you.

During the next few hours, we will focus on the scientific and clinical rationale driving Eagle's hospital-based pipeline and commercial products and lay out for you Eagle's value proposition for patients, the health care system and shareholders.

We will showcase the strength of these development programs as well as our recently acquired approved assets, including Enalare's ENA-001, an agnostic respiratory stimulant being developed by Enalare for the potential treatment of postoperative respiratory depression, community drug overdose and Apnea of Prematurity.

As a reminder, we acquired approximately a 14% equity stake in Enalare earlier this year and have an option to purchase

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot